Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Large Growth in Short Interest

Dogwood Therapeutics, Inc (NASDAQ:DWTX) saw a large increase in short interest in October. As of October 15th, there was short interest totaling 62,406 shares, an increase of 60.4% from the September 30th total of 38,895 shares. Approximately 0.2% of the shares of the stock are short sold. Based on an average trading volume of 76,074 shares, the days-to-cover ratio is presently 0.8 days.

Dogwood Therapeutics Stock Performance

NASDAQ DWTX opened at $1.04 on Wednesday. The stock’s 50 day simple moving average is $1.62 and its 200-day simple moving average is $1.97. Dogwood Therapeutics has a 1-year low of $0.90 and a 1-year high of $7.04.

Dogwood Therapeutics (NASDAQ:DWTX) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.20). As a group, sell-side analysts forecast that Dogwood Therapeutics will post -0.80 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Dogwood Therapeutics in a report on Wednesday, September 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Dogwood Therapeutics in a research note on Thursday, October 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Dogwood Therapeutics currently has an average rating of “Hold” and a consensus price target of $12.00.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for diseases associated with viral activation. The company’s programs are designed to address conditions for which persistent or reactivated viral activity may contribute to symptoms and disease progression.

Its lead investigational product, IMC-1, is an oral combination of the antiviral drug famciclovir and the anti-inflammatory drug celecoxib. The company has evaluated IMC-1 in fibromyalgia and has also investigated its potential use in other conditions, including symptoms associated with long COVID.